Pharmaceutical News

RSS

Polio immunization campaign begins across West and Central Africa

More than 85 million children under five years old will be immunized against polio in 19 countries across West and Central Africa in a massive example of cross-border cooperation aimed at stopping a year-long polio epidemic.

10 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.

10 Mar 2010

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

10 Mar 2010

$Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures$

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

10 Mar 2010

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

An analysis of comparative effectiveness studies finds that few compare medications with nonpharmacologic interventions, and few examine safety or cost-effectiveness, according to a study in the March 10 issue of JAMA.

10 Mar 2010

Study provides first formal analysis of comparative effectiveness research on new therapies

An analysis by researchers at the Keck School of Medicine of the University of Southern California has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective.

10 Mar 2010

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

Mylan today reported that it has identified multiple flaws within a purported bioequivalence study sponsored by Bayer Inc. of Canada. The study compared Bayer's antihypertensive Adalat(R) XL(R) tablets, 60 mg, marketed in Canada, to Mylan's approved generic version, Mylan-Nifedipine Extended Release tablets, 60 mg, marketed in Canada.

10 Mar 2010

Early administration of metformin can prevent long-term complications of diabetes: Study

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.

10 Mar 2010

Augmentation with ketone bodies improves cognitive function in AD patients

Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced data which showed that augmentation with ketone bodies significantly improved cognitive function in Alzheimer's disease (AD) patients.

10 Mar 2010

Researchers take first step in development of vaccine against pregnancy-associated malaria

By managing to express the protein that enables red blood cells infected with the malaria agent Plasmodium falciparum to bind to the placenta and by deciphering its molecular mechanisms, a team of researchers from CNRS and the Institut Pasteur has taken an important first step in the development of a vaccine against pregnancy-associated malaria.

10 Mar 2010

2010 European LDN Conference: LDN can be used as effective treatment for people with MS

People with MS (Multiple Sclerosis) and others suffering with a range of often debilitating inflammatory conditions such as Chronic Fatigue Syndrome and Fibromyalgia, will take heart from advances in treatment for their conditions, and will follow events at The 2nd European LDN Conference with interest.

10 Mar 2010

U.N. official addresses increasing drug addiction in developing countries

The U.N. Office on Drugs and Crime (UNODC) on Monday warned of an impending "health disaster facing developing countries if wealthy nations fail to control drugs," Agence France-Presse reports. During a speech delivered in Vienna, UNODC Executive Director Antonio Maria Costa pointed to "increasing use of heroin in East Africa, cocaine in West Africa, and synthetic drugs in the Middle East and South East Asia as warning signs" of a growing drug problem in impoverished nations (3/8).

10 Mar 2010

Winners of NMSIS scholarship award

Two winners have been selected for the Promising New Investigators Travel Scholarship Awards given annually by the Neuroleptic Malignant Syndrome Information Service (NMSIS).

10 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

Review suggests ion exchange resins are not effective for hyperkalemia

For more than half a century, products containing ion exchange resins have been used in patients with dangerously high levels of potassium. However, there is no convincing evidence that these products are actually effective, according to an article appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

10 Mar 2010

Supreme Court to hear case on vaccine side effects

The Associated Press: The Supreme Court will hear a case to decide whether drug makers can be sued by families who claim their children have suffered health problems from vaccines, going against a 1986 federal law that shields drug makers from most lawsuits and instead sets up a federal vaccine court to handle disputes.

10 Mar 2010

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.

10 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Pharmaceutical News

Polio immunization campaign begins across West and Central Africa

Small study shows eprotirome decreases LDL cholesterol

DSPA's lurasidone NDA accepted for FDA review

Eprotirome lowers bad cholesterol, triglycerides and Lp(A) without statin side effects

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Long-term use of bisphosphonates may adversely affect bone quality and increase risk of atypical fractures

Few CE studies compare medications with nonpharmacologic interventions, and examine safety or cost-effectiveness

Study provides first formal analysis of comparative effectiveness research on new therapies

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

Early administration of metformin can prevent long-term complications of diabetes: Study

Augmentation with ketone bodies improves cognitive function in AD patients

Researchers take first step in development of vaccine against pregnancy-associated malaria

2010 European LDN Conference: LDN can be used as effective treatment for people with MS

U.N. official addresses increasing drug addiction in developing countries

Winners of NMSIS scholarship award

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Review suggests ion exchange resins are not effective for hyperkalemia

Supreme Court to hear case on vaccine side effects

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News